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Zusammenfassung
Hintergrund: Trotz verbesserter Behandlungsmöglichkei-
ten bei Lungenkarzinomen stellt sich die adäquate Be-
handlung von Hirnmetastasen als schwierig dar. Insbe-
sondere bei kranialer Rezidivbildung nach Ganzhirnbe -
strahlung und vorangegangener Chemotherapie fehlen
jegliche Therapieoptionen. Tyrosinkinase-Inhibitoren wie
Erlotinib mit seiner etablierten Aktivität beim nicht-klein-
zelligen Lungenkarzinom können bei dieser Patientenpo-
pulation eine zusätzliche Therapieoption darstellen. Pa-
tienten und Methoden: Diese Arbeit stellt 2 gleichartige
Kasuistiken vor und beschreibt die Ergebnisse eines
 solchen Ansatzes. Ergebnisse: Beide Patienten zeigten
anhaltende kraniale und pulmonale Remissionen bei
gleichzeitiger Symptomverbesserung. Schlussfolgerung:
Die beobachteten Überlebenszeiten von 18 bzw. 15 Mo-
naten seit Auftreten der Hirnmetastasen sowie ein pro-
gressionsfreies Überleben von 9 bzw. 6 Monaten sind
 bemerkenswert. Eine weitergehende Untersuchung des
Einsatzes so genannter «targeted therapies» nach erfolg-
ter Ganzhirnbestrahlung erscheint viel versprechend.
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Summary
Background: With the current improvements in primary
lung care, the long-term control of brain metastases be-
comes a clinical challenge. No established therapeutic
approaches exist for cranial relapse after response to
previous radiotherapy and systemic therapy. Tyrosine ki-
nase inhibitors like erlotinib with its proven activity in
non-small cell lung cancer may provide clinical benefits
in such patients. Patients and Methods: Two case reports
are presented illustrating the efficacy of erlotinib in pa-
tients with recurrent brain metastases and parallel tho-
racic progression. Results: Both patients showed lasting
partial remissions in the brain and lung, and clinical
symptom improvement. Conclusion: The observed sur-
vival times of above 18 and 15 months, respectively,
since occurrence of cranial disease manifestation in line
with the achieved progression-free survival times of 9
and 6 months by the erlotinib third-line therapy are re-
markable. The use of targeted therapies after whole-
brain irradiation should be investigated more systemati-
cally in prospective clinical trials.
Introduction
Brain metastases are a common feature of lung cancer, and
are gaining more and more attention as combined modality
treatment and efficient new drug therapies have improved
local control and overall survival rates. Brain metastases from
lung cancer are the most common type of intracranial neo-
plasm. 20–40% of patients with non-small cell lung cancer
(NSCLC) develop CNS metastases at some point in the
course of their disease [1]. Radiotherapy remains the corner-
stone of treatment for NSCLC patients with brain metastases:
Whole-brain radiotherapy (WBRT) is the accepted standard
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therapy in patients with multiple metastases – a pattern often
associated with metastasizing lung cancer [2]. However, pa-
tients treated with WBRT show, despite acceptable overall re-
sponse rates (ORR) of 60%, an unsatisfying outcome with
high rates of recurrent disease. Apart from patients with fa-
vorable prognostic factors belonging to recursive partitioning
analysis (RPA) class I and considered as candidates for local
curative therapy approaches, the majority of patients has a
poor diagnosis with a median survival of about 3–4 months [3,
4]. In the case of recurrent brain metastases, no standard ther-
apeutic options exist. Because recurrent brain metastases are
indicators of very limited survival and decreasing performance
status, therapeutic alternatives such as stereotactic radio-
surgery (SRS) for single metastases are urgently needed [5].
WBRT may qualify as a therapeutic alternative in cases where
surgical resection or SRS were used before as front-line ap-
proaches for local control [6]. Chemotherapy as a salvage op-
tion after WBRT has been investigated in a number of trials;
only modest activity has been observed in patients with recur-
rent brain metastases from various malignancies [7, 8]. In a
phase II trial investigating oral tyrosine kinase (TK) inhibitor
gefitinib, 18 previously irradiated patients (WBRT completed
3 months before enrolment) drew a clinical benefit from ther-
apy: the disease-control rate was significantly improved, and
the progression-free survival prolonged (4 vs. 2 months). 4 ob-
jective cranial remissions (ORR 10%) were reported [9]. 2
Japanese case series describing their clinical experience on
gefitinib-treated brain metastases (14 and 15 patients, respec-
tively) also included single reports of treatment benefits in re-
current cranial disease [10, 11].
For the oral epidermal growth factor receptor (EGFR) TK in-
hibitor erlotinib, no experiences except 1 casuistic report doc-
umenting a complete cerebral response in a patient with re-
current brain metastases after WBRT and second-line chemo-
therapy, have been published [12]. Here, we report the out-
come of 2 patients with recurrent brain metastases after
WBRT and subsequent chemotherapy, who received erlotinib
monotherapy as a salvage therapy.
Patients and Materials
Since the end of 2004, erlotinib has been routinely used in our hospital.
Prior to its marketing authorization in autumn 2005, the drug was provid-
ed by the manufacturer via an expanded access program. Until spring
2006, approximately 150 patients who failed standard first-line combina-
tion therapy received oral erlotinib in accordance with the prescribing in-
formation. Encouraging results in patients with brain metastases led to a
retrospective analysis of cases who received erlotinib after previous cra-
nial radiation. The 2 selected cases were the ones in which new cranial as
well as thoracic progression were observed after WBRT. Patients under-
went systematic control examinations every month including a complete
blood count, the standard clinical chemistry, serum creatinine, and liver
function tests. Radiological controls of the primary tumor were done
monthly and completed by bimonthly magnetic resonance imaging and
computer tomography controls for thoracic and cranial disease and, if ap-
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plicable, by adequate imaging techniques for other sites of metastatic dis-
ease manifestation. RECIST criteria were applied to assess complete re-
sponses (CR), partial responses (PR), stable disease (SD), and progressive
disease (PD) [13]. Respiratory function testing was systematically carried
out at time of therapy start and in monthly intervals. Disease-related
symptoms were recorded using the National Cancer Institute’s (NCI)
grading system for adverse events. 
Results
Table 1 summarizes the patient characteristics and major
treatment outcomes. Both patients had a comparable prognos-
tic profile in terms of gender, histology, disease stage, and RPA
class at the time of cranial disease manifestation. In both pa-
tients, cranial disease manifestation occurred after a success-
fully completed first-line therapy. As both patients did not re-
quire rapid relief of intracranial pressure by surgical means,
WBRT was the option of choice. The subsequent treatment
sequence and the therapy results for Patient A (multiple brain
metastases – the most prominent one left-sided occipital) and
Patient B (singular lesion right-sided temporal) are presented
in figure 1. 
Tumor relapse after WBRT resulted for Patient A in the oc-
currence of new cranial lesions with further increase in num-
ber and size after second-line chemotherapy. Parallel thoracic
progress, the occurrence of 2 hepatic and of osseous lesions
(lumbar vertebrae and ribs) and an impressive rise of tumor
marker CEA completed the picture of a general clinical dete-
rioration. As a promising therapeutic alternative with a
proven survival benefit in late-stage NSCLC patients, erlotinib
therapy was commenced in July 2005. Figure 2 depicts the ex-
cellent radiological response in the chest and brain. Due to
new hepatic progression in April 2006, erlotinib therapy was
stopped 2 weeks later despite ongoing cranial and thoracic
 remission. The patient died in May 2006 following general
 disease progression.
In Patient B, recurrent tumor progression after WBRT and
second-line therapy was documented with increased thoracic
tumor infiltration, hepatic tumor manifestation and cranial re-
Table 1. Patient demographics for both cases receiving erlotinib salvage
therapy
Case 1 (Patient A) Case 2 (Patient B)
Age and gender 40-year-old woman 63-year-old woman
Histology adenocarcinoma adenocarcinoma
Smoking status nicotine abuse until 1992 non-smoker
TNM stage (first IV (T3N3M1 G3) IV (pT2N0M1)
diagnosis)
Radiotherapy (WBRT) 40 Gy (46 Gy boost left- 40 Gy
occipital)
Prognostic RPA class [3] II II
WBRT: Whole-brain radiotherapy: RPA: recursive partitioning analysis.
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lapse. 3 new intracerebral metastases (parieto-occipital, right
frontal, and left occipital) were detected after a 9-month peri-
od of disease stabilization. Erlotinib therapy started in Octo-
ber 2005 and resulted in almost CR in the brain as well as in
the disappearance of the diffuse thoracic infiltration (images
not shown). The lasting objective remission of above 9 months
was accompanied by an impressive clinical remission with a
remarkable amelioration of dyspnea, cough, chest pain, loss of
appetite, and headaches. Erlotinib was stopped in December
2006 after occurrence of osseous metastases requiring partial
laminectomy of the axis and the atlas. The patient died in May
2007 after further disease progression.
Apart from single episodes of infection, no adverse events
were recorded in both patients except mild to moderate rash,
well known as a class effect of EGFR inhibitors. Hematology
results were normal, for clinical chemistry slightly elevated
liver transaminase levels (grade I toxicity SGOT, AP, and
GGT) were observed in both cases. Fixed-dose corticoid ther-
apy was maintained during erlotinib therapy to control symp-
toms of vertigo in Patient A.
Discussion
With the current improvements in primary lung care, the long-
term control of brain metastases becomes a clinical need. The
explorative use of systemic therapeutic options like chemo-
therapy or new biological agents like TK inhibitors is there-
fore required. The detection of rapid cerebral tumor progres-
sion after WBRT and the occurrence of peritumoral attendant
edema, as observed in our patients, are signs of an already dis-
torted blood-brain barrier in favor of drug therapy [14].
The observed objective remissions of the cerebral metastases
in both cases are strong indicators for the clinical activity of
TK inhibitors in such patients. Cases of simultaneous cerebral
and thoracic tumor responses in recurrent disease that last for
more than 6 months have been very rarely described in the
literature. Simultaneous tumor responses after WBRT have
not been described so far [9–11]. The possibility to control
tumor progression in such different compartments is thought
to affect survival. The availability of differing therapies itself is
an option for survival prolongation as well.
A retrospective review of 4 SWOG studies with stage IIIA/B
patients showed that the relapse in the brain and other sites
compared to relapse in the brain alone resulted in shorter sur-
vival (4.5 vs. 10.3 months). Adenocarcinomas were shown to
be overall more likely to fail in the brain [15]. On the other
hand, adenocarcinoma histology and non-smoking are signifi-
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Fig. 1. Schematic presentation of both cases, indicating the pattern of
progression, the principal therapeutic interventions, and the treatment
outcomes (BCa = Bronchial carcinoma; CR = complete response; PR =
partial response; SD = stable disease; LN = lymph node; mts = months;
TKI = tyrosine kinase inhibition; WBRT = whole-brain radiotherapy).
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Fig. 2. Case 1. Response to erlotinib in the primary tumor and in the
brain (case history shown in fig. 1).
cant independent predictors of survival in erlotinib patients, as
recently showed by exploratory multivariate analysis of a piv-
otal phase III trial [16]. These features may help to interpret
the presented 2 clinical courses with noteworthy overall sur-
vival times of 18 and 15 months, respectively, since detection
of brain metastasis. The achieved lasting symptom control in
both patients – recurrent brain metastases are known to be
usually symptomatic [17] – is of tremendous clinical value and
deserves further investigation to understand the added value
of TK inhibitors in the management of patients suffering from
brain metastases.
Conclusion
The observed primary tumor shrinkage in addition to de-novo
induction of objective remissions in brain metastases that re-
occurred after initial WBRT requires attention. The observed
survival times of above 18 and 15 months, respectively, since
occurrence of cranial disease manifestation in line with the
achieved lasting cranial and thoracic remission times and
symptom control are noteworthy. The best sequential use of
targeted therapies after WBRT should be investigated in
prospective clinical trials.
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